Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the trial miss was a significant setback that could curb demand for CagriSema, temper long-term sales hopes and leave Novo struggling to win back share in the fast-growing obesity treatment market."
— J.P. Morgan analysts , Executive
"Sigo siendo muy optimista con respecto a CagriSema."
— Mike Doustdar , Executive
Key People
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaTdmamc4QU9IekYyT2hOdlVOdlowVjFnZE84b29mN3RuNXFUMURRaUEwTUkzMEwxVllJT3NzdHo3ZjNoYmJmZk41QUpkSTRacmdCd2ZpSVkxdE1icFVXUVVOVUExblRobUpuT2FUSV8td3dCUS00dm5NYU5LYmFTTEdLT0lhQm9naEczT2lySU9GSS1ZUFpEZnNCemFVUk9lejMxR2RBVFNScFBRamlpbEpjQU1iX0RmVjlJVXZJR0k2T2dGZkJWVWItaDY4czE3YkdTT1Fab05tUQ?oc=5" target="_blank">Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out</a> <font color="#6f6f6f">Reuters</font>
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy’s launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly’s tirzepatide in a trial.
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk ha sufrido una nueva caída en Bolsa tras anunciar que los ensayos clínicos de su nuevo medicamento contra la obesidad, CagriSema, no alcanzaron el criterio principal de efectividad frente a su competidor Tirzepatida, comercializado por Eli Lilly.
Similar Stories
Related coverage based on topic and tags
Novo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PMTarget lifts annual forecasts again as Fiddelke's turnaround takes root - Reuters
Target lifts annual forecasts again as Fiddelke's turnaround takes root Reuters
August 19, 2026 at 01:56 PMBirkenstock raises revenue forecast on strong demand, shares jump - reuters.com
Birkenstock raises revenue forecast on strong demand, shares jump reuters.com
August 13, 2026 at 11:29 AMAs Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
As Hims prepares for peptides launch, Wall Street cautious on prospects this year Reuters
August 12, 2026 at 06:34 PM